SciSparc (SPRC) FCF Margin (2016 - 2018)

SciSparc (SPRC) posted FCF Margin of 81.35% for Q4 2018, down 56.19% sequentially from 52.08% in Q3 2018, and down 2139.0% YoY from 3.99% in Q4 2017.

SciSparc (SPRC) FCF Margin (2016 - 2018) Analysis & Trends

SciSparc has reported FCF Margin for 3 years, with the latest figure at 81.35% in Q4 2018.

Quarterly FCF Margin fell 2139.0% year-over-year to 81.35% in Q4 2018, while the trailing twelve-month figure through Dec 2018 was 79.89% (up 46.0% YoY) and the FY2025 annual result came in at 483.29%, down 9187.0% from the prior year.
FCF Margin fell to 81.35% in Q4 2018 per SPRC's latest filing, from 52.08% in the prior quarter.
Over five years, FCF Margin peaked at 30.08% in Q1 2017 and troughed at 132.75% in Q2 2017.
A 3-year average of 84.05% and a median of 80.27% in 2016 frame the typical range for FCF Margin.
The widest YoY moves for FCF Margin: up 3933 bps in 2017, down 5356 bps in 2017.
Over 3 years, FCF Margin stood at 128.73% in 2016, then jumped by 53 bps to 59.96% in 2017, then plunged by 36 bps to 81.35% in 2018.
According to Business Quant data, FCF Margin over the past three periods registered 81.35%, 52.08%, and 111.03% for Q4 2018, Q3 2018, and Q2 2018 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	13.35%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	22.62%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-22.35%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	70.82%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	41.07%
10	SciSparc	836,385.99	836,385.99	-	-

Download Data